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myopathies
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Abstract
Background: The idiopathic inflammatory myopathies (IIMs) are a group of rare conditions characterised by muscle
inflammation (myositis). Accurate disease activity assessment is vital in both clinical and research settings, however,
current available methods lack ability to quantify associated variation of physical activity, an important consequence
of myositis.
This study aims to review studies that have collected accelerometer-derived physical activity data in IIM populations,
and to investigate if these studies identified associations between physical and myositis disease activity.
Methods: A narrative review was conducted to identify original articles that have collected accelerometer-derived
physical activity data in IIM populations. The following databases were searched from February 2000 until February
2019: Medline via PubMed, Embase via OVID and Scopus.
Results: Of the 297 publications screened, eight studies describing accelerometer use in 181 IIM cases were identified.
Seven out of the eight studies investigated juvenile dermatomyositis (JDM) populations and only one reported on an
adult-onset population. Population sizes, disease duration, accelerometer devices used, body placement sites, and
study duration varied between each study.
Accelerometer-derived physical activity levels were reduced in IIM cohorts, compared to healthy controls, and studies
reported improvement of physical activity levels following exercise programme interventions, thus demonstrating
efficacy.
Higher levels of accelerometer-derived physical activity measurements were associated with shorter JDM disease
duration, current glucocorticoid use and lower serum creatine kinase. However, no clear association between muscle
strength and accelerometer-derived physical activity measures was identified.
Conclusions: The use of accelerometer-derived physical activity in IIM research is in its infancy. Whilst knowledge is
currently limited to small studies, the opportunities are promising and future research in this area has the potential to
improve disease activity assessment for clinical and research applications.
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Background
The idiopathic inflammatory myopathies (IIMs) are a
group of rare (annual incidence of 1.5–10 per million
person-years [1], prevalence of 14 per 100,000 [2]) auto-
immune conditions that can cause widespread inflamma-
tion and damage [3, 4]. A number of IIM subtypes are
recognised, including dermatomyositis (DM), juvenile DM
(JDM), polymyositis (PM) and inclusion body myositis.
The most common manifestation of the IIMs is muscle
inflammation, termed “myositis”. Each episode of myositis,
if left untreated, results in irreversible muscle breakdown,
disability and early mortality [5, 6]. Therefore, in clinical
settings, the ability to identify and quantify the severity of
active myositis is imperative, to allow appropriate treat-
ment with the aim of preventing damage. Further, the
availability of valid measurements of myositis disease
activity is essential in research settings, e.g. to evaluate the
efficacy of interventions.
A number of measurements of myositis disease activity
currently exist and include manual muscle testing via the
MMT-8, serum creatine kinase (CK) levels and validated
questionnaires, such as the Health Assessment Question-
naire Disability Index (HAQ-DI). JDM-specific disease
activity can also be assessed by measures such as the
Childhood Myositis Assessment Scale (CMAS), Childhood
Health Assessment Questionnaire (CHAQ) and the Paedi-
atric Quality of Life Inventory (PEDS-QL). A number of
valid measurements of myositis disease activity have been
assimilated into the International Myositis Assessment
and Clinical Studies Group (IMACS) “Disease Activity
Core Set Measures” [7], which is currently used as the
gold-standard of myositis disease activity assessment in
both clinical and research settings.
These measurements of myositis disease activity, al-
though accurate, only capture specific aspects of disease
activity, and do not necessarily objectively assess the
patient-experienced consequence of myositis – namely re-
duced ability to carry out physical activities due to active
muscle disease or irreversible muscle damage [8]. A qualita-
tive study by Alemo Munters et al. identified that ability to
carry out physical activities, including walking, participating
in social activities and cycling were particularly affected in a
myositis population [9]. Importantly, this study also identi-
fied that limitations of these physical activities are not
wholly assessed in the HAQ-DI and Myositis Activities Pro-
file (MAP) [10], two leading methods of patient-reported
disease activity assessment - only 21% of reported disabil-
ities were covered by the HAQ-DI and only 32% were
covered by the MAP.
Objective assessment of physical activity may provide
a novel method for myositis disease activity assessment.
Here, we take the World Health organisation definition
of physical activity as “any bodily movement produced
by skeletal muscles that requires energy expenditure”
[11]. Worsening myositis leads to reduced force gener-
ation capability predominantly of proximal limb muscles
[12, 13]. Subsequent slower walking speed and reduced
stride length, as reported by Siegel et al. [14], result in
patient-reported walking difficulty, particularly whilst
climbing stairs. A number of studies have confirmed the
impact of myositis upon physical activity, along with the
association between myositis disease activity and phys-
ical activity [15–17]. Alexanderson et al. showed that in
a myositis cohort, within the first year after diagnosis
and treatment initiation, improvement of the Functional
Index of myositis test, a measure of physical activity, was
associated with improvement of the MMT-8 and reduc-
tion of CK [15].
A number of methods of assessing physical activity are
available. The gold-standard measurement of energy ex-
penditure, and therefore physical activity, is the “doubly
labelled water” (DLW) method [18]. DLW is water with
hydrogen and oxygen molecules replaced by traceable
isotopes. Following ingestion and attainment of equilib-
rium within the body, serial blood or urine measure-
ments of the concentration of the isotopes can be used
to estimate the body’s metabolic rate. Although accurate,
this technique is time-consuming, expensive, and not
suited to measuring physical activity over prolonged
continuous periods in a “real-world” setting (i.e. when
the study participant is going about their daily activity).
The need for physical activity measurement in real-world
settings has given rise to a number of more practical
methods. One such technique is the use of accelerometer
devices. Accelerometers are small, non-invasive, light-
weight, portable devices that can measure acceleration in
one or more geometric plane (Fig. 1). Modern “capacitive”
accelerometers comprise a small micro electro-mechanical
system with a proof mass attached to the end of a canti-
lever beam, which is surrounded by a set of fixed beams.
External acceleration deflects the proof mass and generates
a variation of capacitance between the fixed beams. This
capacitance variation generates an electrical signal, which
Fig. 1 Image of internal components of an accelerometer device –
thigh worn SENS Motion Plus device, which measures 20mm× 50
mm× 3.5 mm. Reproduced with kind permission of SENS Innovation
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is then converted into a digital or analog output. This out-
put can be used to quantify acceleration in a particular
directional plane [19, 20].
Accelerometers typically measure acceleration in a single
plane (uniaxial) or three orthogonal planes (triaxial). Accel-
erometers are capable of measuring tri-axial acceleration at
high sampling rates, typically 50–100Hz. Sampling at such
a high rate over prolonged periods of time provides a tem-
poral characterisation of physical activity, thus enabling
detection of frequent (i.e. daily) changes. The acceleration
data can either be analysed in its “raw” format or processed
into a number of “composite” measures, such as number
of steps in a time period, distance travelled or intensity of
physical activity (typically categorised as sedentary, light,
moderate or vigorous). Therefore, composite outputs from
accelerometer-containing devices can be used to object-
ively summarise physical activity and identify temporal
changes, for example differentiating periods of physical
activity from sedentary behaviour, or identifying changes in
levels of activity following an intervention. The interpret-
ation of accelerometer-derived measurement in medical
research is dependent on a number of important factors,
such as body site placement (e.g. wrist, thigh, lower back),
duration of use, and device used. Further, study population
factors, such as disease of study interest, disease duration,
presence of comorbidities, control group use, and behav-
ioural factors such as lifestyle and living environment, also
greatly influence the interpretation of collected data.
Therefore, with the need for more accurate myositis
disease activity assessment and the opportunity of phys-
ical activity assessment using accelerometers, a review of
studies to date on this topic will provide a useful sum-
mary of current knowledge. It will also provide an
understanding of future research needs in this area.
This review aims to identify studies that have used
accelerometer-derived physical activity data in studies of
myositis populations, collate and compare reported
physical activity data and lastly, investigate if these stud-
ies identified associations between physical activity and
measures of myositis disease activity.
Methods
A narrative review was conducted to identify original articles
that have used accelerometer devices in the myositis popula-
tions/cohorts. The following databases were searched from
February 2000 until February 2019: Medline via PubMed,
Embase via OVID and Scopus. The following medical
subject headings (MeSH) terms were used to identify appro-
priate studies: “myositis”, “accelerometry”, “exercise test” and
“exercise”. The “myositis” MeSH term encompasses the
DM, PM, and inclusion body myositis subtypes. Each identi-
fied study’s references were also examined for further appro-
priate studies. Studies were included if they were written in
English, studied physician-confirmed human myositis
cases, and measured physical activity using accelerometer-
containing devices. Case reports were excluded.
The abstract of each identified study was reviewed for
eligibility and excluded where appropriate. Full text
review of all potentially eligible studies was subsequently
carried out. Only studies that fulfilled the inclusion
criteria were included in the review.
Conference abstracts were not included in the search
due to the likely insufficient methodology and results
details required to fully compare studies and identified
relationships between accelerometer-derived physical
activity and measures of myositis disease activity.
Ethical approval was not required for this study.
Results
The initial search returned 297 studies. Following re-
moval of 12 duplicates, 28 animal studies and a further
249 that did not meet the inclusion criteria, eight dis-
tinct articles, which utilised accelerometer-derived data
to represent physical activity in a total of 181 myositis
cases, were identified (Fig. 2), details in Tables 1 and 2.
The studies varied with respect to populations investi-
gated, devices used, site of device placement and dur-
ation of study, each of which will be considered in turn,
before we compare findings and address the reported
associations between physical activity and myositis dis-
ease activity.
Populations investigated
Seven out of the eight studies used accelerometers in
JDM populations [21–27] and only one, Bachasson et al.
[28], reported on an adult-onset population. Both
Mathiesen et al. and Berntsen et al. reported the findings
from populations comprising participants both younger
than and older than 18 years of age – however all study
participants had experienced myositis onset aged youn-
ger than 18 years. Population sizes ranged from five to
45 study participants. Disease duration prior to study
commencement varied between each study, from newly
diagnosed cases to 36 years after disease onset. Bachasson
et al. was the only study to report accelerometer data that
was collected from the time of first treatment following
diagnosis [28].
Devices
Actical, ActiGraph, Sense Wear and GENEActiv (Fig. 3)
devices were used. Each accelerometer-containing device
collects acceleration magnitude multiple times each
second and/or provides a summarized measure of phys-
ical activity. Measures of physical activity included the
“Euclidean Norm Minus One” (GENEActiv device) [28],
time spent in light, moderate or vigorous states (Actical,
ActiGraph GT3X devices) [21, 23, 24, 26, 27], “counts”
per minute (CPM, ActiGraph GT1M device) [22, 27]
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and number of steps recorded in 48 h (Sense Wear
device) [25].
The study by Bachasson et al. was the only one not to
report a summary measure of physical activity, such as
step count [28]. They reported the mean daily “vector
magnitude”; the vector magnitude was calculated as the
“Euclidean Norm Minus One” (ENMO). ENMO is
calculated by summing the squared acceleration of each
of the three accelerometer axes at each time point (i.e.
Euclidean Norm) and then subtracting the gravitational
component, which is 1 g (1 g = 9.81 m/s2). The assump-
tion is that increases of the mean daily vector magnitude
indicates increasing levels of physical activity. Vector
magnitude, being a simple mathematical operation, may
preserve the relevant complexity and variation of
physical activity; this contrasts to complex, composite
measures such as step count which may lose important
variation because in practice, these algorithms are con-
founded by unknown factors and developed for different
populations than the one under study.
Six studies reported summary variables related to inten-
sity of physical activity, measured in “counts”, as collected
by ActiGraph GT3X and Actical devices [21–24, 26, 27].
The number of counts in a minute can be used as a proxy
representation of intensity of physical activity. A single
count represents an acceleration measurement exceeding
a pre-specified threshold. Subsequently, each time period
is assigned as corresponding to sedentary (< 100 cpm),
light (> 100 and < 2295 cpm), and moderate-to-vigorous
(> 2295 cpm) activity, depending on the number of counts
detected in a minute. Mathiesen et al. was the only study
to report CPM, without subsequently ascribing inactive,
light, moderate or vigorous intensity [22].
Riisager et al. used a Sense Wear body monitoring sys-
tem [25], which detects steps based on accelerometer
data using a data-driven machine learning algorithm –
i.e. steps are detected when the pattern of collected ac-
celerometer data correspond to step-associated signals;
however, details of the algorithm used to detect steps is
not available as it is proprietary information. The
number of steps per 48 h period was reported as their
surrogate measurement of physical activity.
Site of device placement
A wide variety of body sites for accelerometer placement
were used in the reviewed studies, including wrist [28],
upper arm [25], waist [23] and hip [21, 27]. Studies by
Mathiesen et al. [22] and Habers et al. [26] did not expli-
citly state what site was used, however the manufacturers
of the employed accelerometer devices advise them to be
Fig. 2 Articles identified, eligible for review and included in the narrative review
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worn on the hip at the mid-axillary line. The site of accel-
erometer placement has an important impact upon study
methodology, data interpretation and analysis. For ex-
ample, walking speed estimation may vary between arm
and thigh-worn accelerometers, as arm swing may limit
accurate estimation. Studies have attempted to identify
the most appropriate site of body placement in healthy
states and certain disease areas [29–32], however each
research question necessitates careful consideration of
body site placement to ensure the provision of appropriate
data. With myositis predominantly affecting proximal
limb muscles and subsequently affecting gait, as described
previously, it is plausible that lower limb placement would
be most appropriate.
Duration of data collection
The duration of accelerometer data collection varied
between each study. Duration of accelerometer data
collection periods ranged from seven to 84 days. Most
studies collected accelerometer-derived data continu-
ously throughout 7 day periods. However, studies by
Riisager et al. [25] and Habers et al. [26] recorded two
separate periods of accelerometer data, prior to and
following 12 week exercise intervention programmes,
with the aim of assessing for the effect of the
intervention upon physical activity. A data collection
period long enough to detect changes of disease activity
is required; short 7 day periods may limit the ability to
detect substantial change. The use of two separate data
collection periods by Riisager et al. and Habers et al.
may improve the ability to detect changes in disease ac-
tivity without the need for prolonged, continuous
periods.
Accelerometer-derived physical activity levels in myositis
populations
Quantifiable levels of accelerometer-derived physical
activity were reported by a number of the identified
studies (Table 2) and comparison across studies revealed
a number of relationships.
Time Spent in MVPA was the most commonly reported
accelerometer-derived physical activity measurement
[21, 23, 26, 27]. Across all studies, where reported,
myositis populations spent similar proportions of time
in MVPA, ranging from 2.2–3.7% (prior to intervention,
where applicable), thus indicating consistency, despite
variations in devices employed and populations studied.
When compared to control cohorts, physical activity
levels appeared to be lower in myositis cohorts; however
study limitations, such as small populations, limit
Table 2 Reported accelerometer-derived physical activity levels in myositis cohorts
Authors Counts per
minute
Mean no. steps
in 48 h
Sedentary
% of day
Light %
of day
Moderate %
of day
Vigorous %
of day
MVPA %
of day
Riisager et al. [25] Pre-training
N = 21
16,412
Post-training 21,079
Habers et al. [26] a Pre-training
N = 26
83.0 14.0 2.8 0.1 2.9
Post-training 80.0 15.0 4.6 0.1 4.7
Stephens et al. [21] b N = 15 37.7 12.3 1.4 0.6 2.2
Pinto et al. [23] b JDM cohort
N = 19
69.4 28.0 3.7 c
Control cohort
N = 19
66.1 29.3 4.6 c
Berntsen et al. [27] b “Active” disease
N = 16
351 d 38.0 11.9 3.5 e
“Inactive” disease
N = 29
321 d 40.6 11.8 3.0 e
Control group
N = 45
423 d 39.4 11.3 4.2 e
Mathiesen et al. [22] b < 18 years of age
N = 19
513
> = 18 years of age
N = 12
322
aAccelerometer device was worn throughout 24 h periods for 7 days
bAccelerometer data from non-sleeping hours was analysed
cP-value > 0.05 derived from Mann-Whitney U-test
dP-value < 0.01 derived from Wilcoxon signed rank test
eP-value < 0.01 derived from t-test
JDM Juvenile dermatomyositis, MVPA Moderate to vigorous physical activity
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identification of definitive differences. Both Pinto et al.
[23] and Berntsen et al. [27] demonstrated that their
JDM populations spent less time in MVPA, compared
to healthy controls: Pinto et al. reported that their
JDM cohort spent 3.7% of each day in MVPA, com-
pared to 4.6% in the control cohort, although this dif-
ference did not reach statistical significance (Mann-
Whitney U-test p-value > 0.05), possibly in part due
to the small (n = 19) cohort size. Berntsen et al. [27]
demonstrated that their JDM group spent 3.5% of
each day in MVPA, compared to 4.2% in the control
group (t-test p-value < 0.01). Berntsen et al. also dem-
onstrated a significantly lower CPM level in their
JDM group, compared to the control group: 351 vs
423 CPM, respectively (Wilcoxon signed rank test p-
value < 0.01). Mathiesen et al. [22] reported mean
counts per minute from a JDM cohort – 513 in those
younger than 18 years. Although they did not directly
compare these findings with a healthy control popula-
tion within the same study, they did compare against
reference values from a study of healthy 9 and 15 year
old children by Andersen et al. [33], who reported
similar physical activity levels ranging 412–789 CPM.
These comparisons suggested no statistically signifi-
cant difference to the age and sex-matched healthy
controls.
Associations between accelerometer-derived physical
activity data and myositis disease activity
Five out of the eight studies investigated associations
between accelerometer-derived physical activity data and
myositis disease activity variables/states. Only one of
these studies (Bachasson et al. [28]) primarily aimed to
investigate this association whilst the other studies re-
ported associations whilst investigating other relation-
ships [23, 25–27].
Bachasson et al. [28] and Riisager et al. [25] each investi-
gated the association between accelerometer-derived
physical activity and a number of myositis disease activity
measurements including muscle strength via MMT-8
scores, which, as discussed previously, is a valid measure-
ment of disease activity. Bachasson et al. reported a posi-
tive association, whereas Riisager et al. did not. Bachasson
et al. found that improvement of accelerometer-derived
data (ENMO), using GENEActiv devices, followed longi-
tudinal improvements in MMT-8 scores, CK levels and
Short Form Health Survey (SF-36) questionnaire scores
over the first 6 months after diagnosis and treatment initi-
ation. No formal statistical analysis was carried out due to
the small study population size (n = 5). The ENMO
ranged from 12 to 22 mili g (a unit of acceleration) at
baseline and 22 to 45 mili g after 6 months of treatment.
This increase, however, may not represent a meaningful
change, with a study by Bakrania et al. demonstrating
GENEActiv-derived mean ENMO values of 8 mili g for
standing still and 65 mili g for “self-paced free living walk-
ing” [34]. Although increased ENMO was associated with
stronger (higher) MMT-8 scores, the relatively high base-
line values (range 105–140, maximum value = 150) pre-
cluded detection of substantial increases after 6 months of
treatment (range 145–150), due to ceiling effect. The
observed increase of ENMO also corresponded with re-
ductions of CK (baseline range 1375–6366 IU/L, 6 months
after treatment initiation range 50–300 IU/L), which indi-
cates reducing disease activity, and increase in SF-36
scores (baseline range 20–40, 6 months after treatment
initiation range 48–90), which indicate improving quality
of life. The authors therefore concluded that associations
exist between myositis disease activity and ENMO-derived
physical activity.
Pinto et al. [23] investigated associations between phys-
ical activity intensity (represented by number of counts per
minute recorded via Actigraph GTX accelerometers: < 100
cpm= sedentary, > 100 and < 2295 cpm= light and > 2295
cpm=moderate-to-vigorous) and a number of myositis
disease activity measures including the CMAS, the CHAQ,
Fig. 3 Wrist worn GENEActiv accelerometer device. Reproduced
with kind permission of Activinsights
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disease activity score (DAS), manual muscle testing, CK
levels, current and cumulative dose of glucocorticoids and
disease duration [23]. Analysis was performed via calcula-
tion of Pearson’s correlation coefficients; no adjustment for
potential confounding variables, such as age or gender, was
performed. They identified that increased time spent in a
sedentary state (r = 0.65, p-value = < 0.01) and shorter time
in moderate to vigorous physical activity state (r = − 0.51,
p-value = 0.03) was associated with longer JDM disease
duration. Further, they identified that more time spent in a
moderate to vigorous physical activity state was associated
with current glucocorticoid use (r = 0.75, p-value = < 0.01).
They reported no association between physical activity and
the CHAQ (r = − 0.27, p-value = 0.27) and a number of
other myositis disease activity assessment methods, includ-
ing the PEDS-QL (r = 0.07, p-value = 0.78).
Riisager et al. [25] measured physical activity (via the
number of steps detected in a 48 h period using an
accelerometer-containing Sense Wear armband) along
with the MMT-8 and the CMAS, prior to and following
a 12 week exercise bike programme. Although the num-
ber of steps in a 48 h period increased following the
training programme (16,412 to 21,079, p-value 0.02), no
corresponding change in MMT-8 or CMAS were identi-
fied (no raw figures or statistical comparison results
were supplied).
Habers et al. [26] also investigated the change in
accelerometer-derived physical activity (represented by per-
centage of time spent in inactive, light, moderate and vigor-
ous activity states, as measured by an Actical device over a
7 day period) in a JDM population following a 12week
treadmill and strength exercise programme [26]. In contrast
to the associations identified by Riisager et al. [26], Habers
et al. [26] reported no change in accelerometer-derived
physical activity following the exercise intervention. This is
despite improvement of the median parental disability score
(0.22 vs 0.18), as part of the CHAQ, which, as discussed
previously, is a valid measurement of JDM myositis disease
activity [26]. Statistical comparison of the pre and post-
intervention values was not reported. Therefore, although
direct associations between accelerometer-derived physical
activity and myositis disease activity measurements were
not investigated by Habers et al. [26], the absence of
improvement in physical activity despite improvement of
the CHAQ indicates that an association between the two
may not exist.
The study by Berntsen et al. was the only one to com-
pare physical activity levels between those with “active”
and “inactive” disease activity, according to the PRINTO
criteria for clinically inactive disease [35]. Disease dur-
ation, gender distribution and disease duration were
similar between the two groups. The inactive group (n =
29) demonstrated similar, but significantly lower, phys-
ical activity levels to the active group (n = 16), according
to duration in MVPA (3% vs 3.5% of day, respectively)
and CPM (321 vs 351, respectively, Wilcoxon signed
rank test p-value < 0.01). Although significant, the differ-
ences between the “active” and “inactive” groups are
likely not substantial enough to constitute clinically
meaningful differences. Associations with disease activity
measurements were not investigated for, however both
CPM and MVPA duration were found to be significantly
associated with maximal oxygen uptake (VO2max).
Discussion
The purpose of this narrative review was to 1) identify
studies that have collected accelerometer-derived phys-
ical activity data in studies of myositis populations, 2)
collate and compare reported physical activity data and
3) investigate if these studies identified associations
between physical activity and measures of myositis dis-
ease activity.
Firstly, we have identified that the use of accelerometer-
derived physical activity data in myositis research is
limited. The cause is likely multifactorial, with limited
awareness of the potential benefits of accelerometer use,
additional cost incurred and limited analysis expertise,
each contributing. Additionally, the small number (n = 8)
of studies that have collected such data do so under
incompatible protocols, which makes direct comparison
challenging and may account for some of the conflicting
findings across these studies. No study included more
than 45 participants, thus potentially limiting the ability to
form clear conclusions. Forming a study cohort large
enough for sufficient statistical power is limited by the
rarity of the IIMs (incidence of 11/million person-years,
prevalence of 14/100,000).
Accelerometer use in myositis is still in its infancy,
and so it is useful to reflect on how such devices are
furthering knowledge in other disease areas. Studies have
been able to differentiate the severity of stroke by com-
paring morning peak of accelerometer-derived physical
activity [36, 37]. In multiple sclerosis, disease-specific
“count cut-points” were developed, thus allowing inten-
sity of physical activity to be measured [38, 39]. How-
ever, in musculoskeletal disease, where there is a direct
link between disease and locomotion, research has to
date been less extensive but is beginning to provide im-
portant insights. For example, it has been demonstrated
that accelerometer-derived data can detect improvement
of physical activity following treatment initiation in
patients with rheumatoid arthritis [40].
Quantification of physical activity using proportion of
time spent in MVPA appeared consistent across studies
of myositis populations and, where available, comparison
of MVPA and CPM against healthy controls indicated
lower physical activity levels. It is likely that the observed
reduced MVPA and CPM are due to diminished muscle
Oldroyd et al. BMC Rheumatology            (2019) 3:41 Page 8 of 11
strength capability and exercise tolerance as a result of
active myositis or myositis-induced muscle damage.
Therefore, accelerometer-derived physical activity mea-
surements may provide a useful method of quantification
of differences of exercise tolerance between myositis and
control populations, however further dedicated research
in larger longitudinal cohorts will be required to fully
clarify this capability.
A subset of the reviewed studies (n = 5 [23, 25–
28]) have revealed insights into associations between
accelerometer-derived physical activity data and myositis
disease activity. Higher levels of physical activity were
associated with lower CK (indicating diminished myositis)
and improved SF-36 in an adult cohort [28] and shorter
disease duration and current glucocorticoid use (mean
dose 4.2mg/day) in a juvenile population [23]. Further,
the utility of accelerometer-derived physical activity data
to detect changes following a 12 week exercise programme
in a JDM cohort was illustrated by Riisager et al. where
step count per 48 h increased [25]. This is in contrast to a
study by Habers et al. which reported no detection of
change in accelerometer-derived physical activity follow-
ing a 12 week exercise intervention, despite changes in
muscle function tests [26]. These studies’ findings also in-
dicate that a relationship between accelerometer-derived
physical activity and a number of disease activity measures
(including the CHAQ, CMAS and MMT-8) may not exist,
as no significant associations were identified. Detection of
associations between accelerometer-derived physical activ-
ity and changes in the MMT-8 may have been limited by
a ceiling effect, as demonstrated by Bachasson et al. [28].
Only one study compared accelerometer-derived physical
activity between myositis cases with “active” and “inactive”
disease. Interestingly, significantly lower levels of physical
activity (CPM and mean daily MVPA duration) were
reported in the “inactive” group. Unmeasured factors,
such as degree of muscle damage, current treatment and
involvement in previous exercise programmes was not
reported. Therefore, unfortunately, the limited number of
studies and their sample sizes preclude firm conclusions,
but it remains plausible that physical activity may be a
useful future surrogate measure for myositis disease activ-
ity with some early, promising observed associations.
Further research to investigate the utility of accelerometer-
derived physical activity data in the IIMs and identify
associations with myositis disease activity is warranted.
Quantification of myositis disease activity would ideally
be carried out longitudinally alongside continuous
collection of accelerometer-derived physical activity
data. In addition to disease activity, the IMACS Core
Set Measures can quantify cumulative damage and
differentiate between the two [7]. Therefore, a study to
investigate the relationship between serial changes of
accelerometer-derived physical activity data and the
IMACS Core Set Measures may be the most appropri-
ate approach. This approach could be complemented
by additional frequent (i.e. daily) collection of disease
activity proxy-measurements, such as patient reported
outcome measurements; this approach has shown
promise in a recent study in a population with rheuma-
toid arthritis [41]. None of the identified studies used
the high sampling rate of accelerometers to identify
changes of physical activity across short time periods,
such as day-to-day. This approach has provided important
insights in other disease areas, such as Parkinson’s disease
[42]. Investigation into the association between short term
(e.g. daily) temporal changes of physical activity in IIM
cases could identify previously unrecognised variation of
disease activity and potentially response to treatments in a
clinical trial setting. Further, no identified study collected
accelerometer data over periods longer than 6months.
Measurement of long term changes of accelerometer-
derived physical activity may aid IIM disease course
characterisation and identify factors predictive of relapse
and remission, such as demographics, clinical features or
the presence of myositis specific autoantibodies [43].
Identification of the appropriate method of collection
of accelerometer data in IIM populations is required.
Standardisation will improve comparison between stud-
ies and should allow replication of significant findings.
Aspects of standardisation to be investigated include
type of device, bodily site of placement, duration of data
collection and reporting data format (i.e. raw data vs.
derived physical activity measures). However, important
disease manifestation differences within the IIMs must
be considered, for example predominantly proximal
muscle weakness in DM, compared to distal weakness in
inclusion body myositis; investigation into each IIM
subtype should therefore be considered, allowing focused
standardisation.
The most appropriate method of processing and analys-
ing accelerometer-derived data for the IIMs may be
distinct from other musculoskeletal conditions and should
be identified. For example, particular gait variations in the
IIMs, as discussed previously may impact identification of
steps and calculation of step count. A full description of
the wide variety of algorithms for processing and analysing
accelerometer-derived data is outside the scope of this re-
view, however the implementation of “machine learning”
techniques for data segmentation and detailed physical
activity characterisation, which have proven fruitful in
other rheumatological disease areas [44, 45], is promising.
Conclusions
In summary, this narrative review has identified and sum-
marised the small number of studies that have used
accelerometer-derived physical activity measures in IIM
populations and investigated for associations with myositis
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disease activity. Promisingly, a subset of these studies
identified that a number of validated measures of myositis
disease activity are associated with accelerometer-derived
physical activity, including CK level, disease duration and
glucocorticoid use. However, limited or no association
was found with a number of other disease activity
measures, including the CHAQ, CMAS and MMT-8.
Further research into this potentially worthwhile area is
warranted, with the aim of developing the most appropri-
ate method of collection of accelerometer-derived physical
activity data in IIM populations and clearly delineating
relationships with disease activity measures.
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